Investing.com - Cymabay Therapeu (NASDAQ: CBAY) reported first quarter EPS of $-0.300, in line with the analyst estimate of $-0.300. Revenue for the quarter came in at $0.00 versus the consensus estimate of $5M.
Cymabay Therapeu's stock price closed at $9.140. It is up 97.840% in the last 3 months and up 187.420% in the last 12 months.
Cymabay Therapeu saw 4 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Cymabay Therapeu's stock price’s past reactions to earnings here.
According to InvestingPro, Cymabay Therapeu's Financial Health score is "weak performance".
Check out Cymabay Therapeu's recent earnings performance, and Cymabay Therapeu's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar